IN2014MN01839A - - Google Patents
Info
- Publication number
- IN2014MN01839A IN2014MN01839A IN1839MUN2014A IN2014MN01839A IN 2014MN01839 A IN2014MN01839 A IN 2014MN01839A IN 1839MUN2014 A IN1839MUN2014 A IN 1839MUN2014A IN 2014MN01839 A IN2014MN01839 A IN 2014MN01839A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- relates
- oxides
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D307/08—Preparation of tetrahydrofuran
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603988P | 2012-02-28 | 2012-02-28 | |
| US201261736622P | 2012-12-13 | 2012-12-13 | |
| PCT/IB2013/051555 WO2013128378A1 (en) | 2012-02-28 | 2013-02-27 | Phenyl alkanoic acid derivatives as gpr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01839A true IN2014MN01839A (enExample) | 2015-07-03 |
Family
ID=48225087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1839MUN2014 IN2014MN01839A (enExample) | 2012-02-28 | 2013-02-27 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150072969A1 (enExample) |
| EP (1) | EP2820005A1 (enExample) |
| JP (1) | JP2015508809A (enExample) |
| KR (1) | KR20140138243A (enExample) |
| CN (1) | CN104144920A (enExample) |
| AR (1) | AR090191A1 (enExample) |
| AU (1) | AU2013227266A1 (enExample) |
| CA (1) | CA2866210A1 (enExample) |
| IL (1) | IL234254A (enExample) |
| IN (1) | IN2014MN01839A (enExample) |
| MX (1) | MX2014010272A (enExample) |
| NZ (1) | NZ631569A (enExample) |
| RU (1) | RU2014138894A (enExample) |
| TW (1) | TW201341356A (enExample) |
| WO (1) | WO2013128378A1 (enExample) |
| ZA (1) | ZA201407034B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037705A2 (en) | 2011-09-16 | 2013-03-21 | Fovea Pharmaceuticals | Aniline derivatives,their preparation and their therapeutic application |
| WO2015028960A1 (en) * | 2013-08-28 | 2015-03-05 | Piramal Enterprises Limited | Substituted heterocyclic derivatives as gpr agonists and uses thereof |
| AU2014372114A1 (en) | 2013-11-14 | 2016-06-09 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| US10227360B2 (en) | 2014-02-19 | 2019-03-12 | Piramal Enterprises Limited | Compounds for use as GPR120 agonists |
| US10273230B2 (en) | 2014-07-25 | 2019-04-30 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof |
| US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3177282B1 (en) | 2014-08-08 | 2021-10-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| WO2016032120A1 (ko) * | 2014-08-27 | 2016-03-03 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
| KR101641023B1 (ko) | 2014-08-27 | 2016-07-20 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
| WO2016038540A1 (en) | 2014-09-11 | 2016-03-17 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
| MX2020007283A (es) | 2018-01-08 | 2020-09-10 | Celon Pharma Sa | Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40. |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| WO2024211164A2 (en) * | 2023-04-03 | 2024-10-10 | Trustees Of Dartmouth College | Fatty acid mimetics as modulators of gpr40 and/or gpr120 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5883106A (en) * | 1994-10-18 | 1999-03-16 | Pfizer Inc. | 5-lipoxygenase inhibitors |
| SK281577B6 (sk) * | 1994-10-18 | 2001-05-10 | Pfizer Inc. | Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze |
| JP3400392B2 (ja) * | 1994-10-18 | 2003-04-28 | ファイザー製薬株式会社 | ５−リポキシゲナーゼ阻害剤及び新規医薬組成物 |
| US6403632B1 (en) * | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| AU2271701A (en) * | 1999-12-17 | 2001-06-25 | Abbott Laboratories | Inhibitors of interleukin 5 gene expression |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| US7102008B2 (en) * | 2002-08-01 | 2006-09-05 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
| WO2005054213A1 (ja) * | 2003-12-02 | 2005-06-16 | Shionogi & Co., Ltd. | ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体 |
| EA011010B1 (ru) * | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| CA2626446A1 (en) * | 2005-11-07 | 2007-05-18 | Irm Llc | Compounds and compositions as ppar modulators |
| JP2009537559A (ja) * | 2006-05-18 | 2009-10-29 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の処置のための化合物 |
| ES2379661T3 (es) | 2006-06-27 | 2012-04-30 | Takeda Pharmaceutical Company Limited | Compuestos cíclicos condensados |
| TW200838526A (en) * | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
| BRPI0818253A2 (pt) * | 2007-10-10 | 2015-04-07 | Amgen Inc | Moduladores de gpr40 bifenil substituídos |
| US8217064B2 (en) * | 2007-12-20 | 2012-07-10 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| JP5551707B2 (ja) | 2008-10-15 | 2014-07-16 | アムジエン・インコーポレーテツド | スピロ環ｇｐｒ４０調節因子 |
| JP2012506386A (ja) * | 2008-10-21 | 2012-03-15 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１２０受容体アゴニストおよびその使用 |
| PL2356113T3 (pl) * | 2008-11-14 | 2015-06-30 | Bayer Ip Gmbh | Heterocyklicznie podstawione związki arylowe jako inhibitory HIF |
| BRPI1013937A2 (pt) | 2009-04-22 | 2016-08-09 | Astellas Pharma Inc | compostos de ácido carboxílico |
| WO2010138901A1 (en) * | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| MX2012000752A (es) * | 2009-07-17 | 2012-05-08 | Shire Llc | Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos. |
| DE102009046115A1 (de) * | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
| MA34474B1 (fr) | 2010-07-23 | 2013-08-01 | Connexios Life Sciences Pvt Ltd | Agonistes de gpr40 |
| EP2651930B1 (en) * | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
-
2013
- 2013-02-27 KR KR1020147027497A patent/KR20140138243A/ko not_active Withdrawn
- 2013-02-27 CN CN201380011377.0A patent/CN104144920A/zh active Pending
- 2013-02-27 JP JP2014559335A patent/JP2015508809A/ja active Pending
- 2013-02-27 CA CA2866210A patent/CA2866210A1/en not_active Abandoned
- 2013-02-27 IN IN1839MUN2014 patent/IN2014MN01839A/en unknown
- 2013-02-27 TW TW102106971A patent/TW201341356A/zh unknown
- 2013-02-27 MX MX2014010272A patent/MX2014010272A/es unknown
- 2013-02-27 NZ NZ631569A patent/NZ631569A/en not_active IP Right Cessation
- 2013-02-27 EP EP13719305.8A patent/EP2820005A1/en not_active Withdrawn
- 2013-02-27 AU AU2013227266A patent/AU2013227266A1/en not_active Abandoned
- 2013-02-27 RU RU2014138894A patent/RU2014138894A/ru not_active Application Discontinuation
- 2013-02-27 WO PCT/IB2013/051555 patent/WO2013128378A1/en not_active Ceased
- 2013-02-27 US US14/381,696 patent/US20150072969A1/en not_active Abandoned
- 2013-02-28 AR ARP130100630A patent/AR090191A1/es unknown
-
2014
- 2014-08-21 IL IL234254A patent/IL234254A/en not_active IP Right Cessation
- 2014-09-26 ZA ZA2014/07034A patent/ZA201407034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015508809A (ja) | 2015-03-23 |
| EP2820005A1 (en) | 2015-01-07 |
| TW201341356A (zh) | 2013-10-16 |
| MX2014010272A (es) | 2015-08-14 |
| AR090191A1 (es) | 2014-10-29 |
| CA2866210A1 (en) | 2013-09-06 |
| NZ631569A (en) | 2016-10-28 |
| US20150072969A1 (en) | 2015-03-12 |
| ZA201407034B (en) | 2017-08-30 |
| IL234254A (en) | 2017-03-30 |
| AU2013227266A1 (en) | 2014-10-02 |
| RU2014138894A (ru) | 2016-04-20 |
| CN104144920A (zh) | 2014-11-12 |
| KR20140138243A (ko) | 2014-12-03 |
| WO2013128378A1 (en) | 2013-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01839A (enExample) | ||
| JO3781B1 (ar) | مشتقات الكينولون | |
| MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
| PH12014502524B1 (en) | Carboxylic acid compounds | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| BR112014002202A2 (pt) | macrociclos como inibidores de fator xia | |
| PH12013501704A1 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| EA201270492A1 (ru) | Соединения для лечения дислипидемии и связанных с ней заболеваний | |
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| IN2014MN00697A (enExample) | ||
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| WO2014170842A3 (en) | Substituted alkyl carboxylic acid derivatives as gpr agonists | |
| EA201792597A2 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| IN2013DN02555A (enExample) | ||
| PH12013500671A1 (en) | Novel gpr 119 agonists | |
| IN2014KN01113A (enExample) | ||
| IN2013MN00581A (enExample) | ||
| MX353991B (es) | Agonista del receptor de 5-ht4 como agente procinetico. | |
| PH12015502560B1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
| MY168750A (en) | Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists | |
| MX2009013240A (es) | Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones. | |
| TN2010000318A1 (en) | Fused heterocyclic derivatives and methods of use as c-met inhibitors | |
| TN2013000052A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| TH149194A (th) | องค์ประกอบทางเภสัชกรรมของสารประกอบสไปโร-ออกซินโดล สำหรับการให้ยาเฉพาะที่และการใช้สารนั้นเป็นสารบำบัดรักษา |